Production of Alpha Emitters for Targeted Alpha Therapy

被引：29
|
作者：
Morgenstern, A. [1 ]
Abbas, K. [2 ]
Bruchertseifer, F. [1 ]
Apostolidis, C. [1 ]
机构：
[1] European Commiss, Joint Res Ctr, Inst Transuranium Elements, POB 2340, D-76125 Karlsruhe, Germany
[2] European Commiss, Joint Res Ctr, Inst Hlth & Consumer Protect, I-21020 Ispra, VA, Italy
来源：
CURRENT RADIOPHARMACEUTICALS | 2008年 / 1卷 / 03期
关键词：
Targeted alpha therapy; alpha emitter; production; uranium-230; thorium-227; thorium-226; actinium-225; radium-223; bismuth-213; lead-212; bismuth-212; astatine-211; terbium-149;
D O I：
10.2174/1874471010801030135
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in preclinical studies and/or clinical trials, including (225) Ac / Bi-213, U-230 / Th-226, Th-227 / Ra-223, Pb-212 / Bi-212, At-211 and Tb-149. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.
引用
收藏
页码：135 / 143
页数：9
相关论文
共 50 条
  • [1] Production of Alpha Emitters for Targeted Alpha-Immunotherapy
    Apostolidis, C.
    Bruchertseifer, F.
    Morgenstern, A. F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S87 - S87
  • [2] Targeted therapy using alpha emitters
    Vaidyanathan, G
    Zalutsky, MR
    PHYSICS IN MEDICINE AND BIOLOGY, 1996, 41 (10): : 1915 - 1931
  • [3] Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
    Mehran Makvandi
    Edouard Dupis
    Jonathan W. Engle
    F. Meiring Nortier
    Michael E. Fassbender
    Sam Simon
    Eva R. Birnbaum
    Robert W. Atcher
    Kevin D. John
    Olivier Rixe
    Jeffrey P. Norenberg
    Targeted Oncology, 2018, 13 : 189 - 203
  • [4] Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
    Makvandi, Mehran
    Dupis, Edouard
    Engle, Jonathan W.
    Nortier, F. Meiring
    Fassbender, Michael E.
    Simon, Sam
    Birnbaum, Eva R.
    Atcher, Robert W.
    John, Kevin D.
    Rixe, Olivier
    Norenberg, Jeffrey P.
    TARGETED ONCOLOGY, 2018, 13 (02) : 189 - 203
  • [5] Targeted Radioimmunotherapy and Theranostics with Alpha Emitters
    Pandit-Taskar, Neeta
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2019, 50 (04) : S41 - S44
  • [6] ARE MONOCLONAL ANTIBODIES SUITABLE IN TARGETED RADIONUCLIDE THERAPY USING ALPHA EMITTERS?
    Kumar, Divesh
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 69 - 70
  • [7] Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy
    Tosato, Marianna
    Favaretto, Chiara
    Kleynhans, Janke
    Burgoyne, Andrew R.
    Gestin, Jean-Francois
    Meulen, Nicholas P. van der
    Jalilian, Amirreza
    Koster, Ulli
    Asti, Mattia
    Radchenko, Valery
    NUCLEAR MEDICINE AND BIOLOGY, 2025, 142
  • [8] TARGETED ALPHA THERAPY
    Zalutsky, M. R.
    Vaidyanathan, G.
    RADIOTHERAPY AND ONCOLOGY, 2012, 102 : S195 - S195
  • [9] Production and assessment of astatine-211 for targeted alpha therapy
    Crawford, J.
    Beckham, W.
    Jirasek, A.
    Ruth, T.
    MEDICAL PHYSICS, 2012, 39 (07) : 4627 - 4627
  • [10] Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
    Nelson, Bryce J. B.
    Andersson, Jan D.
    Wuest, Frank
    PHARMACEUTICS, 2021, 13 (01) : 1 - 28
12345